Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Note 7 - Accrued Expenses

12 Months Ended

Dec. 31, 2022

7.	Accrued Expenses

Accrued expenses and other current liabilities consisted of the following (in thousands):

	*Years Ended December 31,*
	*2022*		*2021*
Research and development fees	$	5,758	$	5,682
Compensation expense		3,015		3,581
Accrued license obligations		245		1,541
Accrued accounts payable		1,245		2,980
Lease liabilities		859		1,049
Other current liabilities		483		393
Collaboration cost-sharing obligation		—		1,610
Total	$	11,605	$	16,836